Posts Tagged ‘liver cancer’

Tuesday September 29th, 2015

Dr. Jordi Bruix, new Scientific Director of the Networked Biomedical Research Center for Hepatic and Digestive Diseases

Dr. Jordi Bruix, group leader of the Networked Biomedical Research Center for Hepatic and Digestive Diseases (CIBEREHD) at Hospital Clínic and IDIBAPS, has been appointed CIBEREHD Scientific Director on the CIBER Standing Committee (dependent on the Carlos III Health Institute) held this morning. Dr. Bruix succeeds Dr. Jaume Bosch, also from the Hospital Clinic of  and the IDIBAPS, who occupied this position since 2006.

Read the rest of this entry »

Comments Closed

Categories

Posted in:

Tuesday September 22nd, 2015

IDIBAPS participates in a 5.7M European project to improve knowledge on liver cancer

The Translational Reserarch in Hepatic Oncology IDIBAPS group, led by Dr. Josep M. Llovet, in collaboration with Dr. Roser Pinyol and 8 more researchers, participates in a European project to identify the molecular mechanisms that have a direct impact on the development of hepatocellular carcinoma (HCC). The HEP-CAR project will evaluate the role of these mechanisms in different liver diseases leading to HCC -the infection by hepatitis B and C, overweight or alcohol-. This research initiative, coordinated by the University of Freiburg and in which ten European academic centers are involved, is part of Horizon 2020, the European Comission framework programme for research and innovation, and it is endowed with a budget of 5.7 million euros, one of them corresponding to IDIBAPS.

Read the rest of this entry »

Comments Closed

Categories

Posted in:

Tuesday March 31st, 2015

A pioneering study correlates genetic alterations and environmental factors in liver cancer

IDIBAPS researchers have participated in a pioneering study in hepatocellular carcinoma, the most common liver cancer, in which all the genetic alterations that occur in this type of tumor have been characterized. In an article published in the journal Nature Genetics scientists provide a complete overview of the disease and these genetic alterations associated with the etiology and clinical characteristics, the proposed treatments for patients approved for other cancers, which could be applied in each case. Dr. Josep Maria Llovet, ICREA professor at the IDIBAPS Hepatic Oncology Group and director of the Liver Cancer Program at the Icahn School of Medicine at Mount Sinai (New York), and Dr. Roser Pinyol, researcher at the same group, have participated in this article led by Dr. Jessica Zucman-Rossi, from the INSERM-Paris.

Read the rest of this entry »

Comments Closed

Categories

Posted in:

Thursday July 03rd, 2014

A mutation in progenitor cells identified as origin and therapeutic target for cholangiocarcinoma

In recent years, cancer research has been focused on the identification of mutations in genes involved in tumor development. Nevertheless, the molecular pathways that contribute to the progression of the disease remain quite unknown. The journal Nature publishes a paper in which an international team of scientists, led by Nabeel Bardesy, PhD, from the Harvard Medical School, suggests that a mutation in the IDH enzyme (isocitrate dehydrogenase), that occurs in liver progenitor cells, promotes the progression of cholangiocarcinoma, a type of liver cancer. Josep M. Llovet, MD, PhD, ICREA Research Professor at the HCC Translational Research Lab of the Liver Unit at IDIBAPS and Director of Mount Sinai Liver Cancer Program at the Icahn School of Medicine at Mount Sinai (New York) has collaborated in the study together with Daniela Sia, PhD, and Helena Cornellà, members of the same research group.

Read the rest of this entry »

Comments Closed
Friday January 31st, 2014

Identified a new oncogene which causes liver cancer

 Hepatocellular carcinoma or hepatocellular carcinoma is a type of liver cancer that  constitutes about 80 % of malignant liver tumors. Represents the fifth leading cause of  cancer in the world (750,000 new cases / year) and the second leading cause of cancer  death after lung cancer . It is currently about 4000 cases diagnosed in Spain and 800 cases  in Catalonia. Despite improvements in the techniques of early diagnosis , surgery and  ablative and pharmacological treatments, this cancer still has a very high mortality . In  advanced stages , only one molecular therapy, sorafenib, has been effective . An  international multicenter study led by the Liver Cancer Group of Icahn ‘s Mount Sinai  Hospital in New York, in collaboration with the Institut D’ Biomedical Research August Pi i  Sunyer (IDIBAPS ), has identified an oncogene ( the UHRF1 ) protein in an animal model  capable of generating zebrafish hepatocellular carcinoma. Cancer Cell publishes the results  on line.

Read the rest of this entry »

Comments Closed
Monday November 22nd, 2010

HEPTROMIC, a new approach to Hepatocellular Carcinoma



HEPTROMIC is the first research network funded by the European Commission devoted to the study of Hepatocellular Carcinoma (HCC). It is a 3-year translational research project which aims to solve core problems in the management of HCC, the third most common cause of cancer-related death worldwide. The partners taking part in this initiative have met today in Barcelona in the called kick-off meeting, which officially starts the project. Dr. Josep Maria Llovet, ICREA Research professor at IDIBAPS – Hospital Clínic, and his team lead that project which is meant to change the treatment of this cancer in the next years.

Read the rest of this entry »

Comments Closed